The most undervalued roll-up stock on the ASX, page-4

Paragon Health Care is the cheapest comparable roll up. If you take current consensus for FY 18 which doesn't include recently announced acquisitions, and sits fairly neatly in the middle of the company's guidance for FY18, then the stock is trading on 11.5 X. In my experience its risky to bake in future acquisitions particularly to justify a buy. However I would agree in both cases, the current earnings of both businesses don't require you to stretch assumptions to justify a buy. You can argue about quality of earnings etc but on an absolute valuation basis PGC is clearly "cheaper".